MA46255A - Vaccins anticancéreux - Google Patents

Vaccins anticancéreux

Info

Publication number
MA46255A
MA46255A MA046255A MA46255A MA46255A MA 46255 A MA46255 A MA 46255A MA 046255 A MA046255 A MA 046255A MA 46255 A MA46255 A MA 46255A MA 46255 A MA46255 A MA 46255A
Authority
MA
Morocco
Prior art keywords
cancer vaccines
vaccines
cancer
Prior art date
Application number
MA046255A
Other languages
English (en)
Inventor
Giuseppe Ciaramella
Eric Yi-Chun Huang
Nicholas Valiante
Tal Zaks
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MA46255A publication Critical patent/MA46255A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111Immunoglobulin superfamily
    • A61K39/001114CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588Adjuvants of undefined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA046255A 2015-10-22 2016-10-21 Vaccins anticancéreux MA46255A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562245031P 2015-10-22 2015-10-22
US201562245129P 2015-10-22 2015-10-22
US201562247317P 2015-10-28 2015-10-28
US201562247472P 2015-10-28 2015-10-28
US201662368810P 2016-07-29 2016-07-29

Publications (1)

Publication Number Publication Date
MA46255A true MA46255A (fr) 2019-07-31

Family

ID=58558197

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046255A MA46255A (fr) 2015-10-22 2016-10-21 Vaccins anticancéreux

Country Status (8)

Country Link
US (1) US20180318409A1 (fr)
EP (1) EP3364949A4 (fr)
JP (2) JP2018532777A (fr)
CN (2) CN108430456B (fr)
AU (2) AU2016341309A1 (fr)
CA (1) CA3003090A1 (fr)
MA (1) MA46255A (fr)
WO (1) WO2017070618A1 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3981437A1 (fr) 2014-04-23 2022-04-13 ModernaTX, Inc. Vaccins à base d'acide nucléique
ES2937963T3 (es) 2015-07-21 2023-04-03 Modernatx Inc Vacunas de enfermedad infecciosa
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017031232A1 (fr) 2015-08-17 2017-02-23 Modernatx, Inc. Procédés de préparation de particules et compositions associées
EA201891001A1 (ru) 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
EP3364982A4 (fr) 2015-10-22 2019-04-17 ModernaTX, Inc. Vaccins contre les maladies sexuellement transmissibles
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
SI3718565T1 (sl) 2015-10-22 2022-08-31 Modernatx, Inc. Cepiva za respiratorni virus
EP3364950A4 (fr) 2015-10-22 2019-10-23 ModernaTX, Inc. Vaccins contre des maladies tropicales
WO2017099823A1 (fr) 2015-12-10 2017-06-15 Modernatx, Inc. Compositions et procédés permettant d'administrer des agents thérapeutiques
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
WO2017201340A2 (fr) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucléotides codant la relaxine
MX2019002904A (es) 2016-09-14 2019-09-26 Modernatx Inc Composiciones de arn de alta pureza y métodos para su preparación.
JP6980780B2 (ja) 2016-10-21 2021-12-15 モデルナティーエックス, インコーポレイテッド ヒトサイトメガロウイルスワクチン
EP3538146A4 (fr) 2016-11-11 2020-07-15 ModernaTX, Inc. Vaccin antigrippal
EP3551193A4 (fr) 2016-12-08 2020-08-19 Modernatx, Inc. Vaccins à acide nucléique contre des virus respiratoires
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
AU2017397458A1 (en) * 2017-02-01 2019-08-15 Modernatx, Inc. RNA cancer vaccines
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
EP3595713A4 (fr) 2017-03-15 2021-01-13 ModernaTX, Inc. Vaccin contre le virus respiratoire syncytial
MA52262A (fr) 2017-03-15 2020-02-19 Modernatx Inc Vaccin à large spectre contre le virus de la grippe
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170270A1 (fr) 2017-03-15 2018-09-20 Modernatx, Inc. Vaccin contre le virus varicelle-zona
US20200030432A1 (en) 2017-03-17 2020-01-30 Modernatx, Inc. Zoonotic disease rna vaccines
EP3607074A4 (fr) 2017-04-05 2021-07-07 Modernatx, Inc. Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
WO2019006371A1 (fr) * 2017-06-30 2019-01-03 City Of Hope Compositions et procédés de modulation de l'activité macrophage
CN111212905A (zh) 2017-08-18 2020-05-29 摩登纳特斯有限公司 Rna聚合酶变体
WO2019036685A1 (fr) 2017-08-18 2019-02-21 Modernatx, Inc. Procédés pour analyse par clhp
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
WO2019046809A1 (fr) 2017-08-31 2019-03-07 Modernatx, Inc. Procédés de fabrication de nanoparticules lipidiques
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
GB2574785A (en) 2017-09-15 2019-12-25 Jan Loetvall Method and system for identifying membrane proteins on extracellular vesicles
AU2018397910A1 (en) * 2017-12-27 2020-07-16 Takeda Pharmaceutical Company Limited Nucleic acid-containing lipid nano-particle and use thereof
WO2019148101A1 (fr) 2018-01-29 2019-08-01 Modernatx, Inc. Vaccins à base d'arn contre le vrs
CN111741764A (zh) * 2018-02-12 2020-10-02 生物技术Rna制药有限公司 使用细胞因子编码rna的治疗
KR20210038886A (ko) * 2018-06-27 2021-04-08 모더나티엑스, 인크. 개인화된 암 백신 에피토프 선택
WO2020020444A1 (fr) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Vaccins individualisés pour le cancer
JP2022501367A (ja) * 2018-09-20 2022-01-06 モデルナティエックス インコーポレイテッドModernaTX, Inc. 脂質ナノ粒子の調製及びその投与方法
PL3864163T3 (pl) 2018-10-09 2024-05-20 The University Of British Columbia Kompozycje i układy zawierające pęcherzyki zdolne do transfekcji wolne od rozpuszczalników organicznych i detergentów oraz związane z nimi sposoby postępowania
CA3117670A1 (fr) * 2018-10-29 2020-05-07 Health Research, Inc. Cibles immunotherapeutiques specifiques du cancer generees par traitement medicamenteux chimiotherapeutique
JP2022506839A (ja) * 2018-11-07 2022-01-17 モデルナティエックス インコーポレイテッド Rnaがんワクチン
JP7477888B2 (ja) * 2018-11-15 2024-05-02 ノイスコム アーゲー 個別化された癌ワクチンの作製のための癌変異の選択
WO2020146390A1 (fr) * 2019-01-09 2020-07-16 Exocure Biosciences, Inc. Vésicules dérivées de bactéries et leurs utilisations
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
US20220096539A1 (en) * 2019-01-18 2022-03-31 University Of Georgia Research Foundation, Inc. Salt nanoparticles and compositions and methods of use thereof
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
WO2021028439A1 (fr) * 2019-08-14 2021-02-18 Curevac Ag Combinaisons d'arn et compositions à propriétés immunostimulatrices réduites
US20230022045A1 (en) * 2019-12-03 2023-01-26 Board Of Regents, The University Of Texas System Combination therapies for the treatment of cancer
JP2023515927A (ja) * 2020-02-19 2023-04-17 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 免疫チェックポイント阻害剤による治療に対して腫瘍を感作させる多重膜rnaナノ粒子および方法
CN113521268A (zh) 2020-04-22 2021-10-22 生物技术Rna制药有限公司 冠状病毒疫苗
CN115803333A (zh) 2020-07-02 2023-03-14 生命技术公司 三核苷酸帽类似物、其制备和用途
CN111773381A (zh) * 2020-07-06 2020-10-16 贵阳市第二人民医院 一种靶向tem-1基因疫苗及其构建与应用
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022120560A1 (fr) * 2020-12-08 2022-06-16 深圳市瑞吉生物科技有限公司 Immunosuppresseur sous forme posologique d'arnm et son application dans la préparation d'un médicament pour le traitement de tumeurs
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
CA3223943A1 (fr) * 2021-07-29 2023-02-02 Ugur Sahin Compositions et methodes de traitement du melanome
IL309505A (en) 2021-09-03 2024-02-01 CureVac SE Lipid nanoparticles for nucleic acid delivery
WO2023069625A1 (fr) * 2021-10-20 2023-04-27 Modernatx, Inc. Solutions de substitution de produit médicamenteux
WO2023073228A1 (fr) 2021-10-29 2023-05-04 CureVac SE Arn circulaire amélioré pour exprimer des protéines thérapeutiques
WO2023144330A1 (fr) 2022-01-28 2023-08-03 CureVac SE Inhibiteurs de facteurs de transcription codés par un acide nucleique
WO2023194537A1 (fr) * 2022-04-08 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Nouveaux procédés de production de polynucléotides comprenant des oligonucléotides
WO2023227608A1 (fr) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Vaccin à base d'acide nucléique codant pour un polypeptide antigénique fimh d'escherichia coli
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024004159A1 (fr) * 2022-06-30 2024-01-04 Eps創薬株式会社 Composition de vaccin pour une administration sublinguale
US20240156949A1 (en) 2022-10-28 2024-05-16 Glaxosmithkline Biologicals Sa Nucleic Acid Based Vaccine
CN116083463A (zh) * 2022-12-16 2023-05-09 四川大学华西医院 一种用于增强免疫疗法效果的mRNA及其在制备mRNA疫苗中的用途
CN115671045B (zh) * 2022-12-30 2023-04-07 华南理工大学 非肝靶向的核酸纳米制剂及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6432925B1 (en) * 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
CN1129667C (zh) * 2001-12-26 2003-12-03 中国人民解放军第二军医大学 治疗肿瘤的自体免疫细胞及其制备方法
US20040175813A1 (en) * 2002-05-24 2004-09-09 Kimberly Kline Mutant P53 proteins and uses thereof
BR112012029066A2 (pt) * 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
CA2836494C (fr) * 2011-05-24 2023-01-03 Biontech Ag Vaccins individualises pour le cancer
WO2013006837A1 (fr) * 2011-07-06 2013-01-10 Novartis Ag Emulsions huile dans eau cationiques
EP2791160B1 (fr) * 2011-12-16 2022-03-02 ModernaTX, Inc. Compositions de mrna modifiés
WO2013143555A1 (fr) * 2012-03-26 2013-10-03 Biontech Ag Formulation d'arn pour immunothérapie
AU2013243949A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
AU2013243946A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
US10155031B2 (en) * 2012-11-28 2018-12-18 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
US10130649B2 (en) * 2013-03-15 2018-11-20 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
KR102096796B1 (ko) * 2013-10-22 2020-05-27 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna의 전달을 위한 지질 제형
EP3110401A4 (fr) * 2014-02-25 2017-10-25 Merck Sharp & Dohme Corp. Adjuvants de vaccins sous forme de nanoparticules lipidiques et systèmes d'administration d'antigènes
HUE060907T2 (hu) * 2014-06-25 2023-04-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
WO2017020026A1 (fr) * 2015-07-30 2017-02-02 Modernatx, Inc. Arn épitopes peptidiques concatémériques

Also Published As

Publication number Publication date
AU2024200425A1 (en) 2024-02-15
CN114404581A (zh) 2022-04-29
EP3364949A4 (fr) 2019-07-31
JP2018532777A (ja) 2018-11-08
JP2023024669A (ja) 2023-02-16
US20180318409A1 (en) 2018-11-08
CN108430456B (zh) 2022-01-18
WO2017070618A1 (fr) 2017-04-27
CN108430456A (zh) 2018-08-21
AU2016341309A1 (en) 2018-06-07
CA3003090A1 (fr) 2017-04-27
EP3364949A1 (fr) 2018-08-29

Similar Documents

Publication Publication Date Title
MA46255A (fr) Vaccins anticancéreux
DK3393510T3 (da) Zikavirusvaccine
MA52645A (fr) Vaccins contre le virus respiratoire
DK3218386T3 (da) Modulatorisk polynukleotid
MA46378A (fr) Vaccins hpv16 thérapeutiques
GB201410971D0 (en) Vaccine
DK3119885T3 (da) Antistof-fynomer-konjugater
GB201518684D0 (en) Vaccine
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
MA41107A (fr) Compositions anti-cancéreuses
PL3185899T3 (pl) Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd
DK3198111T3 (da) Forbedret prop
DK3171700T3 (da) Infusionsanlæg
DK3199161T3 (da) Farmaceutisk præparat
DK3129007T3 (da) Vaccinesammensætninger
GB201522132D0 (en) Vaccine
DK3228706T3 (da) Coekspressionsplasmid
DK3205661T3 (da) Hsp70-afledt immunitetsinducerende peptid
HUE064499T2 (hu) Hiszton rákellenes vakcinák
GB201616904D0 (en) Vaccine
DK3405212T3 (da) Cancervacciner
DE112016001834A5 (de) Kanüle
PL3188755T3 (pl) Szczepionka
DK3155004T3 (da) Vaccine til immunkompromitterede værter
DK3089740T3 (da) Farmaceutisk sammensætning